Clinical Focus ›› 2023, Vol. 38 ›› Issue (10): 935-939.doi: 10.3969/j.issn.1004-583X.2023.10.014
Previous Articles Next Articles
-
Received:2023-07-05Online:2023-10-20Published:2024-01-03
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.10.014
| [1] |
Goyale A, Jain A, Smith C, et al. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study[J]. PLoS One, 2021, 16(11):e0260313.
doi: 10.1371/journal.pone.0260313 URL |
| [2] | Farley E, Menter A. Psoriasis: Comorbidities and associations[J]. G Ital Dermatol Venereol, 2011, 146(1):9-15. |
| [3] |
Yin X, Guo X, Liu Z, et al. Advances in the diagnosis and treatment of non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2023, 24(3):2844.
doi: 10.3390/ijms24032844 URL |
| [4] | Karonova T, Belyaeva O, Jude EB, et al. Serum 25(OH)D and adipokines levels in people with abdominal obesity[J]. J Steroid Biochem, 2018, 175:170-176. |
| [5] |
Ono M, Okamoto N, Saibara T. The latest idea in NAFLD/NASH pathogenesis[J]. Clin J Gastroenterol, 2010, 3(6):263-270.
doi: 10.1007/s12328-010-0182-9 pmid: 26190482 |
| [6] | Stanley T, Fourman L, Zheng I, et al. Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease[J]. J Clinl Endocr Metab, 2021, 106(2):e520-e533. |
| [7] |
Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease[J]. J Clin Endocr Metab, 2022, 107(7):1812-24.
doi: 10.1210/clinem/dgac088 URL |
| [8] |
Osganian SA, Subudhi S, Masia R, et al. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Growth Horm Igf Res, 2022, 65:101482.
doi: 10.1016/j.ghir.2022.101482 URL |
| [9] |
Sarmento-Cabral A, Del Rio-Moreno M, Vazquez-Borrego MC, et al. GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner[J]. J Endocrinol, 2021, 248(1):31-44.
doi: 10.1530/JOE-20-0326 pmid: 33112796 |
| [10] |
Sumida Y, Yonei Y, Tanaka S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease[J]. Hepatol Res, 2015, 45(7):771-781.
doi: 10.1111/hepr.12408 pmid: 25163357 |
| [11] | 杨仁国, 贺微微, 罗婷婷. miR-29b-3p靶向IGF1调控非酒精性脂肪肝脂质代谢及肝纤维化[J]. 中国比较医学杂志, 2021, 31(1):66-72. |
| [12] |
Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease[J]. J Clin Endocr Metab, 2013, 98(2):E304-308.
doi: 10.1210/jc.2012-3290 URL |
| [13] | 邹琳, 李铁岩, 钱丽娟, 等. GH/IGF1轴对非酒精性脂肪肝病脂代谢的影响及可能机制研究[J]. 中国现代医学杂志, 2019, 29(3):15-22. |
| [14] |
Hagström H, Stål P, Hultcrantz R, et al. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD-a pilot study[J]. Scand J Gastroentero, 2017, 52(12):1427-1434.
doi: 10.1080/00365521.2017.1379556 pmid: 28927302 |
| [15] | Marques V, Afonso M, Bierig N, et al. Adiponectin leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD[J]. Front Med (Lausanne), 2021, 8:683250. |
| [16] | Yang J, Zhou W, Wu Y, et al. Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: A cohort study[J]. J Int Med Res, 2020, 48(8): 300060520935219. |
| [17] |
Petäjä EM, Zhou Y, Havana M, et al. Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD[J]. Sci Rep, 2016, 6:24740.
doi: 10.1038/srep24740 pmid: 27091074 |
| [18] |
Yao K, Tarabra E, Sia D, et al. Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease[J]. Hepatol Commun, 2022, 6(7):1598-1610.
doi: 10.1002/hep4.1940 pmid: 35312185 |
| [19] | 王平, 马芳玲, 母义明, 等. 2型糖尿病伴高甘油三酯血症患者血清胰岛素样生长因子结合蛋白1水平与胰岛素抵抗的相关性分析[J]. 中国糖尿病杂志, 2007, 15(3):140-141. |
| [20] |
Pan J, Cen L, Zhou T, et al. Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease[J]. J Gastroen Hepatol, 2021, 36(12):3438-3447.
doi: 10.1111/jgh.15627 pmid: 34273192 |
| [21] |
Fahlbusch P, Knebel B, Hörbelt T, et al. Physiological disturbance in fatty liver energy metabolism converges on IGFBP2 abundance and regulation in mice and men[J]. Int J Mol Sci, 2020, 21(11):4144.
doi: 10.3390/ijms21114144 URL |
| [22] |
Chen X, Tang Y, Chen S, et al. IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study[J]. Endocr Connect. 2021, 10(10):1315-1325.
doi: 10.1530/EC-21-0353 pmid: 34524971 |
| [23] |
Liu X, Chen S, Zhang L. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease[J]. Am J Physiol Endocrinol Metab, 2020, 319(1):e34-e42.
doi: 10.1152/ajpendo.00528.2019 URL |
| [24] |
Runchey SS, Boyko EJ, Ioannou GN, et al. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States[J]. J Gastroen Hepatol, 2014, 29(3):589-596.
pmid: 24716226 |
| [25] |
Min HK, Maruyama H, Jang BK, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses[J]. Faseb J, 2016, 30(12):4071-4082.
doi: 10.1096/fsb2.v30.12 URL |
| [26] |
Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease[J]. Hepatol Int, 2007, 1(2):287-294.
doi: 10.1007/s12072-007-9007-4 pmid: 19669352 |
| [27] |
Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease[J]. Growth Horm Igf Res, 2018, 41:7-22.
doi: S1096-6374(18)30047-9 pmid: 29864720 |
| [28] | 赵嘉璐, 李伟文, 蓝伟红, 等. 胰岛素样生长因子结合蛋白4在非小细胞肺癌中的表达及作用[J]. 浙江医学, 2022, 44(6):567-570. |
| [29] |
Demori I, Balocco S, Voci A, et al. Increased insulin-like growth factor binding protein-4 expression after partial hepatectomy in the rat[J]. Am J Physiol Gastrointest Liver Physiol, 2000, 278(3):G384-389.
doi: 10.1152/ajpgi.2000.278.3.G384 URL |
| [30] |
Mazerbourg S, Callebaut I, Zapf J, et al. Up date on IGFBP-4: Regulation of IGFBP-4 levels and functions, in vitro and in vivo[J]. Growth Horm Igf Res, 2004, 14(2):71-84.
pmid: 15123166 |
| [31] |
Polyzos SA, Perakakis N, Boutari C, et al. Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD[J]. J Clin Endocr Metab, 2020, 105(3):e390-400.
doi: 10.1210/clinem/dgz172 URL |
| [32] |
Martínez-Castillo M, Rosique-Oramas D, Medina-Avila Z, et al. Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression[J]. Mol Cell Biochem, 2020, 469(1-2):65-75.
doi: 10.1007/s11010-020-03728-4 pmid: 32301061 |
| [33] |
Colak Y, Senates E, Ozturk O, et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: Association with liver histology[J]. Eur J Gastroen Hepat, 2012, 24(3):255-261.
doi: 10.1097/MEG.0b013e32834e8041 URL |
| [34] |
Nguyen XX, Muhammad L, Nietert PJ, et al. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators[J]. Front Endocrinol (Lausanne), 2018, 9:601.
doi: 10.3389/fendo.2018.00601 URL |
| [35] |
Beattie J, Allan GJ, Lochrie JD, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5): A critical member of the IGF axis[J]. Biochem J, 2006, 395(1):1-19.
pmid: 16526944 |
| [36] |
Su Y, Nishimoto T, Feghali-Bostwick C. IGFBP-5 promotes fibrosis independently of its translocation to the nucleus and its interaction with nucleolin and IGF[J]. PLoS One, 2015, 10(6):e0130546.
doi: 10.1371/journal.pone.0130546 URL |
| [37] |
Umemura A, Itoh Y, Itoh K, et al. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma[J]. Hepatology, 2008, 47(2):493-502.
pmid: 18161051 |
| [38] | 陈照丽, 陈虹, 黄秉仁. 胰岛素样生长因子结合蛋白-6与肿瘤研究进展[J]. 国外医学(肿瘤学分册), 2005, 32(4):253-255. |
| [39] |
Qiu F, Gao W, Wang B. Correlation of IGFBP-6 expression with apoptosis and migration of colorectal carcinoma cells[J]. Cancer Biomark, 2018, 21(4):893-898.
doi: 10.3233/CBM-170947 pmid: 29439316 |
| [40] |
Liso A, Venuto S, Coda ARD, et al. IGFBP-6: At the crossroads of immunity, tissue repair and fibrosis[J]. Int J Mol Sci, 2022, 23(8):4358.
doi: 10.3390/ijms23084358 URL |
| [41] |
Lisowska A, 'Swięcki P, Knapp M, et al. Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease[J]. Adv Med Sci, 2019, 64(1):195-201.
doi: 10.1016/j.advms.2018.08.017 URL |
| [42] |
Yan H, Li T, Wang Y, et al. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease[J]. Clin Exp Pharmacol Physiol, 2019, 46(12):1101-1110.
doi: 10.1111/cep.v46.12 URL |
| [43] |
Liu LX, Huang S, Zhang QQ, et al. Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro[J]. World J Gastroentero, 2009, 15(26):3246-3253.
doi: 10.3748/wjg.15.3246 URL |
| [1] | . [J]. Clinical Focus, 2023, 38(6): 559-563. |
| [2] | . [J]. Clinical Focus, 2023, 38(4): 373-376. |
| [3] | Cao Yumeng, Zhang Haiyan, Liu Lixin. Correlation between pathological changes and serum ferritin and iron levels in nonalcoholic fatty liver disease: A meta-analysis [J]. Clinical Focus, 2023, 38(3): 197-207. |
| [4] | . [J]. Clinical Focus, 2022, 37(9): 846-854. |
| [5] | Zhang Limin, Sun Jun. Predictive value of FIB-4 in patients with metabolic-associated fatty liver disease complicated with colorectal adenomatous polyps [J]. Clinical Focus, 2022, 37(4): 334-338. |
| [6] | Wen Jie. Correlation analysis between atherogenic index of plasma and nonalcoholic fatty liver disease [J]. Clinical Focus, 2022, 37(1): 35-38. |
| [7] | Li Guohuan, Xie Xu, Huang Zhixia, Zhang Mingye, Tang Yunyun. Quantitative evaluation of transient elastography and acoustic radiation force pulse imaging for non-alcoholic fatty liver disease [J]. Clinical Focus, 2021, 36(6): 535-539. |
| [8] | Zhang Ying, Wang Chunsheng. Effects of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in treatment of NAFLD [J]. Clinical Focus, 2021, 36(1): 58-61. |
| [9] | Lu Xiaomin;Wang Zhenning;Yang Jun;Cui Zheng. Detection of serum iron in alcoholic and non-alcoholic fatty liver disease [J]. Clinical Focus, 2015, 30(9): 1033-1035. |
| [10] | WAN Shun-mei;WU Yong-sheng;ZHU Ping;LI Wan-jun;WAN Ping-xin;YANG Wei-jie;PAN Li. Significance of oxygen free radical metabolism in nonalcoholic fatty liver in high-altitude regions [J]. Clinical Focus, 2014, 29(6): 670-671672. |
| [11] | . [J]. CLINICAL FOCUS, 2014, 29(4): 474-477. |
| [12] | . [J]. Clinical Focus, 2013, 28(5): 540-542. |
| [13] | ZHANG Zi-yu;LUO Wen-ming. Relationship of fatty liver detected by B-ultrasound with serum lipid level and hepatic function [J]. Clinical Focus, 2012, 27(23): 2050-2052. |
| [14] | . [J]. Clinical Focus, 2012, 27(22): 1977-1979. |
| [15] | . [J]. Clinical Focus, 2012, 27(17): 1512-1513. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||